Compare Stocks: ALLO, IMNM, RARE, and NRIX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$2.01 +2.0%	$1.95	$0.99 ▼ $4.46	$679.96M	0.48	6.39 million shs	3.69 million shs
IMNM Immunome	$25.03 -3.1%	$21.49	$8.66 ▼ $27.65	$2.92B	2.08	1.05 million shs	881,133 shs
NRIX Nurix Therapeutics	$25.53 +1.2%	$21.26	$8.19 ▼ $25.89	$2.62B	1.79	1.14 million shs	729,410 shs
RARE Ultragenyx Pharmaceutical	$25.91 +0.3%	$27.89	$18.29 ▼ $39.89	$2.55B	0.35	1.79 million shs	3.83 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	+2.03%	+6.91%	-5.19%	-11.84%	+89.62%
IMNM Immunome	-3.06%	+9.97%	+4.25%	+11.54%	+139.29%
NRIX Nurix Therapeutics	+1.23%	+10.00%	+5.02%	+54.54%	+144.07%
RARE Ultragenyx Pharmaceutical	+0.35%	+4.01%	-25.27%	-0.80%	-7.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$2.01 +2.0%	$1.95	$0.99 ▼ $4.46	$679.96M	0.48	6.39 million shs	3.69 million shs
IMNM Immunome	$25.03 -3.1%	$21.49	$8.66 ▼ $27.65	$2.92B	2.08	1.05 million shs	881,133 shs
NRIX Nurix Therapeutics	$25.53 +1.2%	$21.26	$8.19 ▼ $25.89	$2.62B	1.79	1.14 million shs	729,410 shs
RARE Ultragenyx Pharmaceutical	$25.91 +0.3%	$27.89	$18.29 ▼ $39.89	$2.55B	0.35	1.79 million shs	3.83 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	+2.03%	+6.91%	-5.19%	-11.84%	+89.62%
IMNM Immunome	-3.06%	+9.97%	+4.25%	+11.54%	+139.29%
NRIX Nurix Therapeutics	+1.23%	+10.00%	+5.02%	+54.54%	+144.07%
RARE Ultragenyx Pharmaceutical	+0.35%	+4.01%	-25.27%	-0.80%	-7.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.69	Moderate Buy	$8.52	323.99% Upside
IMNM Immunome	2.85	Moderate Buy	$34.18	36.56% Upside
NRIX Nurix Therapeutics	2.80	Moderate Buy	$34.00	33.18% Upside
RARE Ultragenyx Pharmaceutical	2.83	Moderate Buy	$57.82	123.17% Upside

Current Analyst Ratings Breakdown

Latest ALLO, IMNM, RARE, and NRIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2026	RARE Ultragenyx Pharmaceutical	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$47.00 ➝ $45.00
8/4/2026	NRIX Nurix Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$34.00
8/4/2026	RARE Ultragenyx Pharmaceutical	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$43.00 ➝ $35.00
7/29/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/28/2026	NRIX Nurix Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$36.00 ➝ $38.00
7/22/2026	NRIX Nurix Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$23.00 ➝ $31.00
7/21/2026	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$31.00
7/17/2026	IMNM Immunome	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	NRIX Nurix Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	NRIX Nurix Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$30.00 ➝ $34.00
7/10/2026	NRIX Nurix Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $34.00

(Data available from 8/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	34,687.58	N/A	N/A	$1.30 per share	1.55
IMNM Immunome	$6.94M	408.45	N/A	N/A	$5.75 per share	4.35
NRIX Nurix Therapeutics	$83.98M	31.55	N/A	N/A	$5.29 per share	4.83
RARE Ultragenyx Pharmaceutical	$673M	3.80	N/A	N/A	($0.83) per share	-31.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$190.89M	-$0.77	N/A	N/A	N/A	N/A	-56.45%	-40.36%	8/12/2026 (Estimated)
IMNM Immunome	-$212.39M	-$2.38	N/A	N/A	N/A	N/A	-51.15%	-47.32%	N/A
NRIX Nurix Therapeutics	-$264.46M	-$3.45	N/A	N/A	N/A	-928.44%	-76.09%	-57.31%	10/8/2026 (Estimated)
RARE Ultragenyx Pharmaceutical	-$575M	-$5.84	N/A	N/A	N/A	-81.79%	-1,024.42%	-43.78%	N/A

Latest ALLO, IMNM, RARE, and NRIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ALLO Allogene Therapeutics	-$0.1714	N/A	N/A	N/A	$0.00 million	N/A
8/4/2026	Q2 2026	RARE Ultragenyx Pharmaceutical	-$1.22	-$0.90	+$0.32	-$0.90	$183.08 million	$214.00 million
7/9/2026	Q2 2026	NRIX Nurix Therapeutics	-$0.73	-$0.81	-$0.08	-$0.81	$15.29 million	$9.04 million
5/13/2026	Q1 2026	ALLO Allogene Therapeutics	-$0.19	-$0.18	+$0.01	-$0.18	$0.00 million	N/A
5/12/2026	Q1 2026	IMNM Immunome	-$0.60	-$0.48	+$0.12	-$0.48	$0.22 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.65	9.65
IMNM Immunome	N/A	21.68	21.68
NRIX Nurix Therapeutics	N/A	6.34	6.34
RARE Ultragenyx Pharmaceutical	N/A	2.02	1.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
IMNM Immunome	44.58%
NRIX Nurix Therapeutics	N/A
RARE Ultragenyx Pharmaceutical	97.67%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
IMNM Immunome	7.21%
NRIX Nurix Therapeutics	6.70%
RARE Ultragenyx Pharmaceutical	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	345.15 million	299.60 million	Optionable
IMNM Immunome	40	113.25 million	105.09 million	Optionable
NRIX Nurix Therapeutics	300	103.78 million	96.83 million	Optionable
RARE Ultragenyx Pharmaceutical	1,371	98.59 million	93.37 million	Optionable

ALLO, IMNM, RARE, and NRIX Headlines

Recent News About These Companies

Quantinno Capital Management LP Purchases 137,758 Shares of Ultragenyx Pharmaceutical Inc. $RARE

August 8 at 4:47 AM | marketbeat.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Upgraded to Hold at Wall Street Zen

August 8 at 1:49 AM | americanbankingnews.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Upgraded by Wall Street Zen

August 8 at 1:47 AM | marketbeat.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by Analysts

August 7 at 4:28 AM | marketbeat.com

Wells Fargo & Company Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

August 7 at 3:09 AM | americanbankingnews.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Up After Strong Earnings

August 7 at 1:41 AM | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Ultragenyx Pharmaceutical (RARE) and Beam Therapeutics (BEAM)

August 6 at 10:26 PM | theglobeandmail.com

Ultragenyx Pharmaceutical Q2 Loss Narrows as Revenue Rises; 2026 Revenue Guidance Reaffirmed

August 6 at 12:25 PM | finance.yahoo.com

Guggenheim Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

August 6 at 2:30 AM | americanbankingnews.com

Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y

August 5 at 12:51 PM | zacks.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $45.00 by Analysts at Wells Fargo & Company

August 5 at 11:23 AM | marketbeat.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Up on Strong Earnings

August 5 at 10:19 AM | marketbeat.com

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call Transcript

August 5 at 6:00 AM | seekingalpha.com

Ultragenyx Pharmaceutical Q2 Earnings Call Highlights

August 4, 2026 | marketbeat.com

Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

August 4, 2026 | zacks.com

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

August 4, 2026 | zacks.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Posts Earnings Results, Beats Estimates By $0.32 EPS

August 4, 2026 | marketbeat.com

Ultragenyx: Q2 Earnings Snapshot

August 4, 2026 | aol.comA

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

August 4, 2026 | globenewswire.com

Guggenheim Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

August 4, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Boosts Holdings in Ultragenyx Pharmaceutical Inc. $RARE

August 4, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALLO, IMNM, RARE, and NRIX Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$2.01 +0.04 (+2.03%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$2.00 0.00 (-0.25%)

As of 08/7/2026 07:38 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Immunome NASDAQ:IMNM

$25.03 -0.79 (-3.06%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$24.97 -0.06 (-0.24%)

As of 08/7/2026 07:44 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Nurix Therapeutics NASDAQ:NRIX

$25.53 +0.31 (+1.23%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$25.24 -0.29 (-1.14%)

As of 08/7/2026 07:53 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Ultragenyx Pharmaceutical NASDAQ:RARE

$25.91 +0.09 (+0.35%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$26.02 +0.11 (+0.42%)

As of 08/7/2026 07:34 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALLO, IMNM, RARE, and NRIX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALLO, IMNM, RARE, and NRIX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALLO, IMNM, RARE, and NRIX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALLO, IMNM, RARE, and NRIX Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

Immunome NASDAQ:IMNM

Nurix Therapeutics NASDAQ:NRIX

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALLO, IMNM, RARE, and NRIX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALLO, IMNM, RARE, and NRIX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALLO, IMNM, RARE, and NRIX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALLO, IMNM, RARE, and NRIX Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

Immunome NASDAQ:IMNM

Nurix Therapeutics NASDAQ:NRIX

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools